Insufficient capital to fund operations
The company has no operating revenue and expects cash to fund less than 12 months.
- Scope
- Corporate liquidity and continuity of development programs
- Materiality
- high
Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing small-molecule oncology and immunotherapy product candidates. Its pipeline includes TPST-1495 and amezalpat, which are being advanced through preclinical and clinical development for cancer-related indications.
2.50
2.50
| % | |
|---|---|
| Clinical-stage oncology candidates | 100% Small-molecule drug candidates being developed for cancer and related indications. |
| Preclinical research programs | 0% Discovery and early-stage research activities supporting future therapeutic candidates. |
| Clinical development services | 0% Internal and outsourced trial execution, regulatory support, and development operations. |
| Partnering and licensing opportunities | 0% Potential out-licensing or collaboration structures for pipeline commercialization. |
Tempest does not currently sell commercial products, so its direct customers are not traditional end-market buyers...
- Future oncology patientsprimary
Patients with cancer indications who would receive approved therapies through healthcare providers.
- Healthcare providersprimary
Oncologists, hospitals, and treatment centers that would prescribe and administer products.
- Strategic partnerssecondary
Biopharma partners that may license, co-develop, or commercialize pipeline assets.
- CROs and CMOssecondary
Contract research and manufacturing providers used for trials, testing, and supply.
Tempest is headquartered in the United States and its development and commercialization plans are centered on U.S...
- •Headquartered in the United States
- •U.S. regulatory pathway is central to development
- •Potential commercialization may extend outside the U.S.
- •Clinical and manufacturing work is outsourced to third parties
- •Geographic reach may depend on alliance partners
Tempest’s strategy is to advance TPST-1495 in a Phase 2 study and continue developing its clinical-stage pipeline...
01
Advance TPST-1495 in clinical developmentshort-term
Clinical progress is the main value driver for a pre-revenue biotech company.
02
Evaluate strategic alternativesshort-term
Partnerships, licensing, or transactions may provide capital and development support.
03
Use external partners for development and commercializationmedium-term
The company lacks internal sales and marketing infrastructure and needs third-party capabilities.
Tempest faces the core risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and...
Strategic alternatives may not produce a transaction
If no transaction is completed, the company may need to raise capital or wind down.
- Scope
- Enterprise value and continuation of operations
- Materiality
- high
Clinical development failure
Drug candidates may not show sufficient efficacy or safety in trials.
- Scope
- TPST-1495, amezalpat, and future pipeline assets
- Materiality
- high
Third-party manufacturing and trial execution risk
CROs and CMOs can miss deadlines, fail quality requirements, or disrupt supply.
- Scope
- Preclinical studies, clinical trials, and future product supply
- Materiality
- high
Reimbursement and pricing pressure
Even approved therapies may face payer resistance and pricing constraints.
- Scope
- Future commercial uptake and realized revenue
- Materiality
- medium
Research and development expense accruals
Can cause volatility in operating expenses and accrued liabilities
Stock-based compensation
Affects reported losses without immediate cash outflow
Lease accounting
Affects balance sheet leverage and cash commitment disclosures
Going-concern assessment
Influences financial statement presentation and investor risk assessment
INTENSITY THERAPEUTICS, INC.
INTS · Biological Products, (No Diagnostic Substances)
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
PLIANT THERAPEUTICS, INC.
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Indaptus Therapeutics, Inc.
INDP · Pharmaceutical Preparations
MUSTANG BIO, INC.
MBIO · Pharmaceutical Preparations
: 29/04/2026